Swedish Orphan Biovitrum (OTCMKTS:BIOVF) versus Surrozen (NASDAQ:SRZN) Head to Head Analysis
by Sarita Garza · The Markets DailySwedish Orphan Biovitrum (OTCMKTS:BIOVF – Get Free Report) and Surrozen (NASDAQ:SRZN – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.
Volatility and Risk
Swedish Orphan Biovitrum has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500. Comparatively, Surrozen has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500.
Valuation & Earnings
This table compares Swedish Orphan Biovitrum and Surrozen”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Swedish Orphan Biovitrum | $2.89 billion | 6.30 | $48.85 million | $2.01 | 25.40 |
| Surrozen | $3.48 million | 106.34 | -$242.03 million | ($40.55) | -0.79 |
Swedish Orphan Biovitrum has higher revenue and earnings than Surrozen. Surrozen is trading at a lower price-to-earnings ratio than Swedish Orphan Biovitrum, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Swedish Orphan Biovitrum and Surrozen’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Swedish Orphan Biovitrum | 20.67% | 17.92% | 9.30% |
| Surrozen | -2,885.33% | N/A | -112.29% |
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Swedish Orphan Biovitrum and Surrozen, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Swedish Orphan Biovitrum | 0 | 3 | 5 | 0 | 2.62 |
| Surrozen | 1 | 1 | 5 | 1 | 2.75 |
Surrozen has a consensus target price of $61.75, indicating a potential upside of 93.72%. Given Surrozen’s stronger consensus rating and higher possible upside, analysts clearly believe Surrozen is more favorable than Swedish Orphan Biovitrum.
Institutional and Insider Ownership
66.6% of Surrozen shares are owned by institutional investors. 31.7% of Surrozen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
About Swedish Orphan Biovitrum
Swedish Orphan Biovitrum AB, known as Sobi, is a Swedish biopharmaceutical company focused on developing and providing treatments for rare and other serious diseases. Its work centers on hematology, immunology and specialized medicines for conditions with limited treatment options. Sobi’s portfolio includes therapies for blood disorders such as hemophilia, as well as treatments for rare inflammatory and immune-related conditions. The company also develops and commercializes medicines for other rare diseases, working with research and commercial partners where appropriate.
About Surrozen
Surrozen, Inc. is a clinical-stage biotechnology company focused on developing regenerative medicines that selectively activate the Wnt signaling pathway. Wnt signaling plays an important role in tissue development, repair and regeneration, and Surrozen is working to harness the pathway while limiting the potential safety risks associated with broad or uncontrolled activation. The company uses its SWEETS (Surrozen Wnt Engineered Efficacious Therapeutics) platform to discover and engineer antibody-based medicines designed to modulate Wnt signaling in specific tissues.